Your browser doesn't support javascript.
loading
Population Viral Load, Viremia, and Recent HIV-1 Infections: Findings From Population-Based HIV Impact Assessments (PHIAs) in Zimbabwe, Malawi, and Zambia.
Farahani, Mansoor; Radin, Elizabeth; Saito, Suzue; Sachathep, Karampreet K; Hladik, Wolfgang; Voetsch, Andrew C; Auld, Andrew F; Balachandra, Shirish; Tippett Barr, Beth A; Low, Andrea; Smart, Theodore F; Musuka, Godfrey; Jonnalagadda, Sasi; Hakim, Avi J; Wadonda-Kabondo, Nellie W; Jahn, Andreas; Mugurungi, Owen; Williams, Daniel B; Barradas, Danielle T; Payne, Danielle; Parekh, Bharat; Patel, Hetal; Wiesner, Lubbe; Hoos, David; Justman, Jessica E.
Afiliação
  • Farahani M; ICAP at Columbia University, New York, NY.
  • Radin E; ICAP at Columbia University, New York, NY.
  • Saito S; ICAP at Columbia University, New York, NY.
  • Sachathep KK; ICAP at Columbia University, New York, NY.
  • Hladik W; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
  • Voetsch AC; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
  • Auld AF; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Malawi.
  • Balachandra S; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Côte d'Ivoire.
  • Tippett Barr BA; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Zimbabwe.
  • Low A; ICAP at Columbia University, New York, NY.
  • Smart TF; ICAP at Columbia University, New York, NY.
  • Musuka G; ICAP at Columbia University, Zimbabwe.
  • Jonnalagadda S; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
  • Hakim AJ; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
  • Wadonda-Kabondo NW; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Malawi.
  • Jahn A; ITECH-Malawi, Lilongwe, Malawi.
  • Mugurungi O; Ministry of Health and Child Care, Zimbabwe.
  • Williams DB; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
  • Barradas DT; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Zambia and.
  • Payne D; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Malawi.
  • Parekh B; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
  • Patel H; Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
  • Wiesner L; Pharmacology Research Laboratory, University of Cape Town, Cape Town, South Africa; and.
  • Hoos D; ICAP at Columbia University, New York, NY.
  • Justman JE; ICAP at Columbia University, New York, NY.
J Acquir Immune Defic Syndr ; 87(Suppl 1): S81-S88, 2021 08 01.
Article em En | MEDLINE | ID: mdl-33560041
ABSTRACT

BACKGROUND:

HIV population viral load (PVL) can reflect antiretroviral therapy program effectiveness and transmission potential in a community. Using nationally representative data from household surveys conducted in Zimbabwe, Malawi, and Zambia in 2015-16, we examined the association between various VL measures and the probability of at least one recent HIV-1 infection in the community.

METHODS:

We used limiting-antigen avidity enzyme immunoassay, viral load suppression (VLS) (HIV RNA <1000 copies/mL), and antiretrovirals in the blood to identify recent HIV-1 cases.

RESULTS:

Among 1510 enumeration areas (EAs) across the 3 surveys, 52,036 adults aged 15-59 years resided in 1363 (90.3%) EAs with at least one HIV-positive adult consenting to interview and blood draw and whose VL was tested. Mean HIV prevalence across these EAs was 13.1% [95% confidence intervals (CI) 12.7 to 13.5]. Mean VLS prevalence across these EAs was 58.7% (95% CI 57.3 to 60.0). In multivariable analysis, PVL was associated with a recent HIV-1 case in that EA (adjusted odds ratio 1.4, 95% CI 1.2 to 1.6, P = 0.001). VLS prevalence was inversely correlated with recent infections (adjusted odds ratio 0.3, 95% CI 0.1 to 0.6, P = 0.004). The 90-90-90 indicators, namely, the prevalence of HIV diagnosis, antiretroviral therapy coverage, and VLS at the EA level, were inversely correlated with HIV recency at the EA level.

CONCLUSIONS:

We found a strong association between PVL and VLS prevalence and recent HIV-1 infection at the EA level across 3 southern African countries with generalized HIV epidemics. These results suggest that population-based measures of VLS in communities may serve as a proxy for epidemic control.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Viremia / Infecções por HIV / HIV-1 / Carga Viral Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: J Acquir Immune Defic Syndr Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Viremia / Infecções por HIV / HIV-1 / Carga Viral Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: J Acquir Immune Defic Syndr Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2021 Tipo de documento: Article